Medicine · 2026
Suicidality associated with betahistine: A rare case report and systematic review of histaminergic drug-induced depression.
СтатьяКлинический случайСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tang Jiong, Zeng Yuqi, Jiang Xiaoli
Аннотация
RATIONALE: Drug-induced suicidality is a severe and frequently overlooked area within pharmacovigilance. While the traditional focus has centered on psychotropic medications, non-psychotropic drugs acting on histamine receptors may also induce depression and suicidality through central nervous system effects.
PATIENT CONCERNS: A 33-year-old male presented with a chief complaint of "dizziness for 1 week." His dizziness improved after taking a betahistine hydrochloride oral solution, but he subsequently developed symptoms including low mood, emotional detachment, and suicidal ideation.
DIAGNOSES: Given the close temporal relationship between drug intake and symptom onset, rapid improvement after withdrawal, and assessment by the Naranjo scale and World Health Organization-Uppsala Monitoring Centre system, the depressive symptoms with suicidality were preliminarily judged to be "probable" betahistine-associated adverse reactions (grade 1 [mild]).
INTERVENTIONS: Betahistine was discontinued immediately and replaced with difenidol hydrochloride tablets to manage the dizziness.
OUTCOMES: Suicidal ideation resolved completely within 2 days of betahistine discontinuation. No recurrence of psychiatric symptoms was reported during the 3-month follow-up period.
LESSONS: This case emphasizes the need for clinicians and pharmacists to move beyond the cognitive bias that only psychotropic drugs carry a significant suicide risk. Vigilance for potential neuropsychiatric adverse reactions, such as depression and suicidality, should be maintained for all drug classes, particularly for non-psychotropic agents acting on histamine receptors. Timely recognition and drug discontinuation are crucial to ensure patient safety.
PATIENT CONCERNS: A 33-year-old male presented with a chief complaint of "dizziness for 1 week." His dizziness improved after taking a betahistine hydrochloride oral solution, but he subsequently developed symptoms including low mood, emotional detachment, and suicidal ideation.
DIAGNOSES: Given the close temporal relationship between drug intake and symptom onset, rapid improvement after withdrawal, and assessment by the Naranjo scale and World Health Organization-Uppsala Monitoring Centre system, the depressive symptoms with suicidality were preliminarily judged to be "probable" betahistine-associated adverse reactions (grade 1 [mild]).
INTERVENTIONS: Betahistine was discontinued immediately and replaced with difenidol hydrochloride tablets to manage the dizziness.
OUTCOMES: Suicidal ideation resolved completely within 2 days of betahistine discontinuation. No recurrence of psychiatric symptoms was reported during the 3-month follow-up period.
LESSONS: This case emphasizes the need for clinicians and pharmacists to move beyond the cognitive bias that only psychotropic drugs carry a significant suicide risk. Vigilance for potential neuropsychiatric adverse reactions, such as depression and suicidality, should be maintained for all drug classes, particularly for non-psychotropic agents acting on histamine receptors. Timely recognition and drug discontinuation are crucial to ensure patient safety.